Miyoshi Yasuo

ミヨシヤスオ | Miyoshi Yasuo

Affiliation and department：
Job title： Others

Research field (1)： General surgery, pediatric surgery

Research keywords (2)： Oncological surgery , 腫瘍外科

Research theme for competitive and other funds (22)：

2024 - 2027 乳癌患者由来オルガノイド・動物モデルの臨床的有用性の検証と新規治療開発への応用
2022 - 2026 細胞外小胞を用いたリキッドバイオプシーによる癌に対する術前化学療法の効果予測
2022 - 2025 Development of biomarkers and new treatments for metastatic breast cancer by eribulin
2022 - 2025 乳癌における脂質メディエーターを標的とする薬物送達システムを用いた新規治療の開発
2019 - 2022 The role of lipid mediator in the tumor immune microenvironment of breast cancer and its therapeutic application

Show all

Papers (383)：

Eri Ishikawa, Takahiro Watanabe, Takako Kihara, Mamiko Kuroiwa, Miki Komatsu, Sayaka Urano, Masayuki Nagahashi, Seiichi Hirota, Yasuo Miyoshi. The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer. Breast cancer research and treatment. 2024
Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Takayuki Kobayashi, Yuriko Katagiri, et al. Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast cancer research and treatment. 2024
Shogo Nakamoto, Yukiko Kajiwara, Kohei Taniguchi, Akira I Hida, Yuichiro Miyoshi, Takanori Kin, Mari Yamamoto, Daisuke Takabatake, Shinichiro Kubo, Hajime Hikino, et al. Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14. Breast cancer research and treatment. 2024
Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruiz Borrego, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology. 2024. 25. 5. 614-625
Masayuki Nagahashi, Yasuo Miyoshi. Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer. International journal of molecular sciences. 2024. 25. 6

ｍore...

MISC (345)：

内山圭司, 吉丸哲郎, 松下洋輔, 尾野雅哉, 三好康雄, 笹三徳, 片桐豊雅. 乳がん細胞におけるO型糖鎖修飾を介したIRE1の恒常的活性化機構の解明と新規治療戦略の可能性. 日本生化学会大会プログラム・講演要旨集. 2023. 96回. [1T14a-481)]
福池凜, 月本準, 堀井雄登, 竹内美絵, 加守虹穂, 三好瑞希, 篠原康雄, 伊藤孝司. AAVPHP.eBを用いた脳室内単回投与によるNEU1欠損症に対する遺伝子治療. 日本生化学会大会プログラム・講演要旨集. 2023. 96回. [1P-532]
Abdullah Ili S., 松下洋輔, 小松正人, 清谷一馬, 三好康雄, Ohsumi Shozo, 笹三徳, 片桐豊雅, Matsushita Yosuke. 全ゲノム塩基配列決定により明らかとなった日本人家族性乳癌の新たな潜在的感受性遺伝子(Whole-exome sequencing reveals new potential susceptibility gene for Japanese familial breast cancer). 日本癌学会総会記事. 2023. 82回. 953-953
吉丸哲郎, 松下洋輔, 笹三徳, 三好康雄, 片桐豊雅. BIG3-PHB2の相互作用を標的とすることで、HER2陽性乳がんのトラスツズマブ耐性を克服できる(Targeting BIG3-PHB2 interaction overcomes trastuzumab-resistance in patients with HER2-positive breast cancer). 日本癌学会総会記事. 2023. 82回. 1541-1541
内山圭司, 吉丸哲郎, 松下洋輔, 尾野雅哉, 笹三徳, 三好康雄, 片桐豊雅. ゴルジ体-小胞体連携による持続的小胞体ストレス応答を通じたがん微小環境制御機構と新規創薬開発(Tumor microenvironmental control via persistent ER stress response by Golgi-ER collaboration and new therapeutics). 日本癌学会総会記事. 2023. 82回. 1591-1591

ｍore...

Professional career (1)：

Association Membership(s) (7)：

日本癌治療学会 , 日本乳癌学会 , 米国癌学会 , 日本人類遺伝学会 , 日本消化器外科学会 , 日本外科学会 , 日本癌学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page